<p><strong>荷蘭萊頓，2025 年 12 月 8 日：</strong> Pharming Group N.V.（“Pharming”）（Euronext Amsterdam: PHARM/Nasdaq: PHAR）今天宣佈將參加於 2025 年 12 月 11 日在紐約市舉行的 Oppenheimer 罕見疾病峯會。該活動僅限受邀參加，匯聚了專注於罕見疾病的創新公司和投資者。</p>
<p>Pharming 的首席醫學官 Anurag Relan 博士將於東部時間下午 1:50 / 中歐時間晚上 7:50 參與一場關於遺傳性血管神經性水腫（HAE）市場的爐邊談話。</p>
<p>如需與 Pharming 管理團隊安排一對一會議，請聯繫投資者關係部，郵箱為 investor@pharming.com 或您的 Oppenheimer 代表。</p>
<p><strong>關於 Pharming Group N.V.</strong></p>
<p>Pharming Group N.V.（EURONEXT Amsterdam: PHARM/Nasdaq: PHAR）是一家全球生物製藥公司，致力於改善罕見、致殘和危及生命疾病患者的生活。我們正在開發和商業化一系列創新藥物，包括小分子和生物製劑。Pharming 總部位於荷蘭萊頓，且其員工中有相當一部分位於美國。</p>
<p>欲瞭解更多信息，請訪問 www.pharming.com 並在 LinkedIn 上關注我們。</p>
<p><strong>如需進一步公共信息，請聯繫：</strong></p>
<p><strong>投資者關係</strong></p>
<p>Michael Levitan，投資者關係與企業傳播副總裁</p>
<p>電話：+1 (908) 705 1696</p>
<p>郵箱：investor@pharming.com</p>
<p><strong>媒體關係</strong></p>
<p>全球：Saskia Mehring，企業傳播經理</p>
<p>電話：+31 6 28 32 60 41</p>
<p>郵箱：media.relations@pharming.com</p>
<p>美國：Ethan Metelenis（代表 Pharming 的 Precision AQ）</p>
<p>電話：+1 (917) 882-9038</p>
<p>荷蘭：Leon Melens（代表 Pharming 的 LifeSpring 生命科學傳播）</p>
<p>電話：+31 6 53 81 64 27</p>
<ul>
<li>Pharming Oppenheimer Movers in Rare Disease Conference_EN_08DEC25</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBNelEyTXlNME1ESXlOemt4TmpVak1qQXdNRGszTmc9PQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBNelEyTXlNME1ESXlOemt4TmpVak1qQXdNRGszTmc9PQ"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/MmQxNmJjMTQtZWJlOC00MTFiLWFlNDAtYjNlOWE3YmQyMGQ4LTEwMTI1NDktMjAyNS0xMi0wOC1lbg==/tiny/Pharming-Group-N-V-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/MmQxNmJjMTQtZWJlOC00MTFiLWFlNDAtYjNlOWE3YmQyMGQ4LTEwMTI1NDktMjAyNS0xMi0wOC1lbg==/tiny/Pharming-Group-N-V-.png"/></p>

PHAR

<p>Pharming Group N.V. 將於 2025 年 12 月 11 日在紐約市參加 Oppenheimer 罕見疾病峯會。首席醫學官 Anurag Relan 將討論遺傳性血管性水腫市場。該活動為邀請制，匯聚了在罕見疾病領域的創新公司和投資者。Pharming 是一家專注於罕見、致殘性疾病的生物製藥公司</p>

<p><strong>Leiden, the</strong> <strong>Netherlands, December 8, 2025:</strong> Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025 in New York City. This invitation-only event brings together innovative companies and investors focused on rare diseases.</p>
<div class="lb-trans"><p><strong>荷蘭萊頓，2025 年 12 月 8 日：</strong> Pharming Group N.V.（“Pharming”）（Euronext Amsterdam: PHARM/Nasdaq: PHAR）今天宣佈將參加於 2025 年 12 月 11 日在紐約市舉行的 Oppenheimer 罕見疾病峯會。該活動僅限受邀參加，匯聚了專注於罕見疾病的創新公司和投資者。</p>
</div><p>Anurag Relan, M.D., Chief Medical Officer of Pharming, will participate in a fireside chat focused on the hereditary angioedema (HAE) market at 1:50 pm ET / 19:50 CET.</p>
<div class="lb-trans"><p>Pharming 的首席醫學官 Anurag Relan 博士將於東部時間下午 1:50 / 中歐時間晚上 7:50 參與一場關於遺傳性血管神經性水腫（HAE）市場的爐邊談話。</p>
</div><p>To schedule a one-on-one meeting with Pharming’s management team, please contact Investor Relations at investor@pharming.com or your Oppenheimer representative.</p>
<div class="lb-trans"><p>如需與 Pharming 管理團隊安排一對一會議，請聯繫投資者關係部，郵箱為 investor@pharming.com 或您的 Oppenheimer 代表。</p>
</div><p><strong>About Pharming Group N.V.</strong></p>
<div class="lb-trans"><p><strong>關於 Pharming Group N.V.</strong></p>
</div><p>Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.</p>
<div class="lb-trans"><p>Pharming Group N.V.（EURONEXT Amsterdam: PHARM/Nasdaq: PHAR）是一家全球生物製藥公司，致力於改善罕見、致殘和危及生命疾病患者的生活。我們正在開發和商業化一系列創新藥物，包括小分子和生物製劑。Pharming 總部位於荷蘭萊頓，且其員工中有相當一部分位於美國。</p>
</div><p>For more information, visit www.pharming.com and find us on LinkedIn.</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問 www.pharming.com 並在 LinkedIn 上關注我們。</p>
</div><p><strong>For further public information, contact:</strong></p>
<div class="lb-trans"><p><strong>如需進一步公共信息，請聯繫：</strong></p>
</div><p><strong>Investor Relations</strong></p>
<div class="lb-trans"><p><strong>投資者關係</strong></p>
</div><p>Michael Levitan, VP Investor Relations &amp; Corporate Communications</p>
<div class="lb-trans"><p>Michael Levitan，投資者關係與企業傳播副總裁</p>
</div><p>T: +1 (908) 705 1696</p>
<div class="lb-trans"><p>電話：+1 (908) 705 1696</p>
</div><p>E: investor@pharming.com</p>
<div class="lb-trans"><p>郵箱：investor@pharming.com</p>
</div><p><strong>Media Relations</strong></p>
<div class="lb-trans"><p><strong>媒體關係</strong></p>
</div><p>Global: Saskia Mehring, Corporate Communications Manager</p>
<div class="lb-trans"><p>全球：Saskia Mehring，企業傳播經理</p>
</div><p>T: +31 6 28 32 60 41</p>
<div class="lb-trans"><p>電話：+31 6 28 32 60 41</p>
</div><p>E: media.relations@pharming.com</p>
<div class="lb-trans"><p>郵箱：media.relations@pharming.com</p>
</div><p>U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming)</p>
<div class="lb-trans"><p>美國：Ethan Metelenis（代表 Pharming 的 Precision AQ）</p>
</div><p>T: +1 (917) 882-9038</p>
<div class="lb-trans"><p>電話：+1 (917) 882-9038</p>
</div><p>Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)</p>
<div class="lb-trans"><p>荷蘭：Leon Melens（代表 Pharming 的 LifeSpring 生命科學傳播）</p>
</div><p>T: +31 6 53 81 64 27</p>
<div class="lb-trans"><p>電話：+31 6 53 81 64 27</p>
</div><ul>
<li>Pharming Oppenheimer Movers in Rare Disease Conference_EN_08DEC25</li>
</ul>
<div class="lb-trans"><ul>
<li>Pharming Oppenheimer Movers in Rare Disease Conference_EN_08DEC25</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTBNelEyTXlNME1ESXlOemt4TmpVak1qQXdNRGszTmc9PQ" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE0MzQ2MyM0MDIyNzkxNjUjMjAwMDk3Ng=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/MmQxNmJjMTQtZWJlOC00MTFiLWFlNDAtYjNlOWE3YmQyMGQ4LTEwMTI1NDktMjAyNS0xMi0wOC1lbg==/tiny/Pharming-Group-N-V-.png" alt="" original-src="https://ml-eu.globenewswire.com/media/MmQxNmJjMTQtZWJlOC00MTFiLWFlNDAtYjNlOWE3YmQyMGQ4LTEwMTI1NDktMjAyNS0xMi0wOC1lbg==/tiny/Pharming-Group-N-V-.png"/></p>

Pharming Group 將參與 Oppenheimer 罕見病峯會 | PHARM 股票新聞